Introduction
Metronidazole has become a commonly used antimicrobial agent in the treatment of puerperal infections. It is, however, generally recommended that women do not breast-feed during metronidazole therapy [1, 3, 8, 15 ] as a number of studies have demonstrated metronidazole in breast milk in concentrations which do not differ markedly from corresponding maternal blood levels [2, 7, 9, 14] . It has been stated [8] that isolated measurements of a drug in breast milk is of little significance and that both the mother and infant must be examined as drug absorption in the neonate may be limited or facilitated compared to the adult. Also, excretion and metabolism may be decreased in the neonate organism causing accumulation of the drug. To our knowledge no studies have measured comparative levels of metronidazole in mothers and infants during therapeutic administration for puerperal infection in lactating mothers. We have performed such a study measuring the levels of metronidazole and its hydroxy metablite (I) in milk and blood of mothers and their suckling infants with a specific method. The object was to assess the amounts of the drug and its hydroxymetabolite in the infant organism and their rates of clearance. We also analysed a series of simultaneous milk and blood samples in one mother and calculated milk/plasma and infant/mother plasma ratios. 
Curriculum vitae

Material and method
Fifteen mothers in treatment for puerperal endometritis with metronidazole tablets consented to participate. Four of the patients received 400 mg and eleven 200 nig three times daily. All women received additional therapy, thirteen with pivampicillin tablets 350mg and two with erythromycin tablets 500mg three times daily. The medication was started from 0 to 22 days after parturition and all samples collected from at least 1 day after treatment start and up to 9 days after treatment start. 0300-5577/83/0011-0114$02.00 © by Walter de Gruyter & Co. · Berlin · New York Maternal blood samples were collected from two hours after intake of a tablet until next breast-feed irrespective of medication when a simultaneous blood and milk sample were taken. One mother had a series of synchronous blood and milk samples collected, i.e. at 10,30, 60, 120, 180, and 240 minutes after medication. At the time of milk sampling the infants were test weighed and 1 to 2 hours later they had a blood sample taken as peak plasma concentrations occur within 30 minutes to 3 hours after oral administration [4] . The analyses for metronidazole and its hydroxy metabolite (I) in milk and plasma were performed as a specific semi-micro high-pressure liquid Chromatographie method as described by K.AYE and co-workers [10] . The limit of sensitivity was less than 0.1
Results
Concentrations of metronidazole and its hydroxy metabolite (I) in milk and in infant and maternal plasma are shown in Tabs. I and II. Mean and range for maternal and infant plasma levels and milk levels as well as milk/plasma ratios in mothers and infant/mother plasma ratios are shown in Tabs. Ill and IV for metronidazole and hydroxy metabolite (I). Simultaneous milk and blood samples in one woman show almost identical levels of metronidazole and hydroxy metabolite (I) from 10 to 240 minutes after dosing (Tab. V). Judging from milk levels the maximum dose of metronidazole ingested by one infant in one meal was 1.8mg/100mg and assuming a total daily intake of 500 ml and an average neonatal weight of 3.0 kg the amount taken would be 3.0 mg/kg/ day. C m = 12.5 A/g/ml, and Q = 2.4 Mg/ml. If we assume infant and maternal weights to be 3.0 and 70.0 kg and body surfaces to be 0.2 m 2 and 1.8 m 2 infant clearance is 61% and 63% of maternal clearance by weight and 23 % and 24 % by body surface. No adverse reactions were observed in mothers or infants.
Discussion
Breast-feeding involves benefits for the infant and its mother. Administration of drugs to the mother during the lactating period always raises the question of the possible harmful effects of the drug to the infant as virtually all drugs via the milk Tab. II. Concentrations of hydroxy metabolite I in Mg/ml in mothers and infants. Time after dosing/feed in minutes. 11 4 Number patients 11 4 Concentrations of metronidazole in reach the infant organism. The safety evaluation of metronidazole is based mainly on animal studies and clinical experience derived from the adult population [5, 13] . Absorption of metronidazole in neonates may be altered and as metronidazole is primarily excreted by the kidneys, the newborn may accumulate the drug resulting in higher concentrations than in the adult organism. Studies [2, 7, 9, 14] dealing with metronidazole administration to lactating women involve only few infants and only one study besides the present has analysed infant blood levels. GRAY and co-workers' [9] study involved 10 mothers who were given a single tablet of 200 mg metronidazole. Mean concentrations in breast milk varied between 1.3 and 3.4 Mg/ml and between 1.8 and 3.9 Mg/ml in serum. Blood tests from 5 babies contained no detectable metronidazole and in 5, levels ranged from 0.05 to 0.4 g/ml. The maximum amount ingested by one infant calculated from test weighings was 0.41 mg. As expected these figures all range below our findings which are based on the therapeutic administration of metronidazole to the mothers. AMON et aL [2] examined 6 puerperae who were given 250 mg metronidazole orally twice daily. The highest level in breast milk was found to be 6.8Mg/ml and the maximum amount actually taken by the newborn was 0.17 mg/kg/100 ml milk which is about one third of the amount we have estimated. The coefficient of distribution milk: Serum was below 1.0 in four and above 1.0 in two mothers which compares well with our milk/plasma ratios. The administration of metronidazole in the Study Group [14] report is the only one comparable to a Tab. V. Simultaneous maternal milk, and plasma concentrations in Mg/ml of metronidazole and hydroxy metabolite (I) in one mother receiving 1200 mg metronidazole daily. No pharmacokinetic studies of metronidazole have involved neonates why the intestinal absorption is unknown. Assuming that the mean maternal and infant plasma levels represent steady state concentrations we calculated the infant total clearance to be around 60% by weight and around 24% by body surface of the maternal clearance. This finding is in good accordance with the clearance ratios found for other antimicrobial chemotherapeutics such as gentamycin [12] . The fraction is apparently independent of the daily intake. The maximum intake by an infant in our study was calulated to be 3.0mg/kg with 500ml milk intake per day which is well below the advocated 10-20mg/kg metronidazole dosage in the treatment of infants. On the other hand, a 1200 rng daily intake of metronidazole by the mother may result in almost therapeutic levels.in infants.
The hydroxy metabolite (I) like the parent compound is known to possess antimicrobial and mutagenic activity. The antimicrobial activity of the metabolite tested on clostridial species was found to be 30% of metronidazole [6] whereas the mutagenic activity tested in vitro with Salmonella Typhimurium was found to be 10 times higher [11] . The significance of these findings in humans is unknown. In all instances we found the levels of the hydroxy metabolite (I) to be considerably lower than those of metronidazole.
Our conclusion is that infants do receive metronidazole via breast milk in considerable doses and attain measurable levels in their organisms. On these grounds, it seems wise to prescribe metronidazole with caution to lactating women. The ultimate decision whether to stop or continue breastfeeding ( during metronidazole therapy still has to be based on our insufficient knowledge of the possible long-term harmful effects of the drug on the neonate, as only few and mild instant adverse reactions are seen.
Summary
In order to assess the amounts of metronidazole and its clearance in suckling neonates whose mothers received the drug in therapeutic doses, we measured its levels in maternal plasma and milk and in infant plasma. Eleven mothers receiving 600 mg metronidazole daily and 4 receiving 1200mg and their 15 infants had milk and plasma levels determined with a specific semi-micro high-pressure liquid Chromatographie method. Maternal mean plasma levels were 5.0 Mg/ml, range 1.0-11.6 Mg/ml (600mg/day) and 12.5 Mg/ml range 3.7-17.9 Mg/ml (1200mg/day) and corresponding infant plasma levels were 0.8 Mg/ml, range 0.3-1.4 Mg/ml and 2.4 Mg/ml, range 0.6-4.9 Mg/ml. Maternal milk/plasma ratio was 1 and baby/mother plasma ratio was 0.15, independent of dosage (Tab. I). The levels of metronidazole hydroxy metabolite (I) were all below those of metronidazole (Tab. II). Simultaneous milk and blood samples showed almost identical levels (Tab. III). Infant total clearance of metronidazole was calculated to be ca. 60 % of maternal clearance by body weight and 24% by body surface, independent of dosage, while maximum infant metronidazole intake was estimated to be 3.0mg/kg/day assuming a daily intake of 500ml milk. It is recommended to avoid simultaneous breastfeeding and metronidazole therapy until possible harmful longterm effects on the neonates are known.
Keywords: Infant clearance, infant plasma levels, lactation, metronidazole. La moyenne des taux plasmatiques maternels est de 5 Mg/ml, avec des ecarts compris entre l et 11,6 Mg/ml (600 mg/ jour) et 12,5 Mg/ml avec des ecarts allant de 3,7 a 17,9 Mg/ml (1200 mg/jour), tandis que les taux plasmatiques correspondants des enfants sont de 0,8 Mg/ml, avec des ecarts de 0,3 ä 1,4 Mg/ml et 2,4 Mg/ml, avec des ecarts de 0,6 ä 4,9 Mg/ml. Le rapport lait maternel/plasma est de I et le rapport plasmatique enfant/mere est de 0,15, independamment des dosages (Tab. I). Les taux de metabolite hydroxyle du metronidazole (I) sont tous en-dessous de ceux du metronidazole (Tab. II). Les echantillons simultanes de lait et de sang montrent des taux ä peu pres identiques (Tab. III). La clearance totale du metronidazole chez l'enfant a ete determinee ä 60 % de la clearance maternelle en fonction du poids corporel, et ä 24 % en fonction de la surface corporelle sans lien avec la posologie, alors que Tapport maximum de metronidazole chez l'enfant a ete estime ä 3 mg/Kg/jour, ce qui correspond ä une quantite journaliere de 500 ml de lait. II est recommande d'eviter l'allaitement au sein lors des traitements par metronidazole, tant qu'un eventuel effet nocif ä long terme chez le nouveau-ne n'aura pas ete elimine.
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